166 related articles for article (PubMed ID: 33739455)
21. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab.
Avery RA; Hwang EI; Jakacki RI; Packer RJ
JAMA Ophthalmol; 2014 Jan; 132(1):111-4. PubMed ID: 24232489
[TBL] [Abstract][Full Text] [Related]
22. Optic pathway gliomas in children with and without neurofibromatosis 1.
Czyzyk E; Jóźwiak S; Roszkowski M; Schwartz RA
J Child Neurol; 2003 Jul; 18(7):471-8. PubMed ID: 12940652
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas.
Greenberger BA; Pulsifer MB; Ebb DH; MacDonald SM; Jones RM; Butler WE; Huang MS; Marcus KJ; Oberg JA; Tarbell NJ; Yock TI
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1060-1068. PubMed ID: 25035209
[TBL] [Abstract][Full Text] [Related]
24. Vision specific quality of life in children with optic pathway gliomas.
Avery RA; Hardy KK
J Neurooncol; 2014 Jan; 116(2):341-7. PubMed ID: 24197987
[TBL] [Abstract][Full Text] [Related]
25. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More.
Kinori M; Armarnik S; Listernick R; Charrow J; Zeid JL
Am J Ophthalmol; 2021 Jan; 221():91-96. PubMed ID: 32283094
[TBL] [Abstract][Full Text] [Related]
26. Neurofibromatosis type 1 and sporadic optic gliomas.
Singhal S; Birch JM; Kerr B; Lashford L; Evans DG
Arch Dis Child; 2002 Jul; 87(1):65-70. PubMed ID: 12089128
[TBL] [Abstract][Full Text] [Related]
27. Orbital optic nerve gliomas in children with neurofibromatosis type 1.
Zeid JL; Charrow J; Sandu M; Goldman S; Listernick R
J AAPOS; 2006 Dec; 10(6):534-9. PubMed ID: 17189147
[TBL] [Abstract][Full Text] [Related]
28. Regression and pseudoprogression of pediatric optic pathway glioma in patients treated with proton beam therapy.
Youn SH; Kim H; Lee SH; Kim JY
Pediatr Blood Cancer; 2022 Mar; 69(3):e29434. PubMed ID: 34766717
[TBL] [Abstract][Full Text] [Related]
29. Optic pathway glioma in children: does visual deficit correlate with radiology in focal exophytic lesions?
Aquilina K; Daniels DJ; Spoudeas H; Phipps K; Gan HW; Boop FA
Childs Nerv Syst; 2015 Nov; 31(11):2041-9. PubMed ID: 26277358
[TBL] [Abstract][Full Text] [Related]
30. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.
Ullrich NJ; Prabhu SP; Packer RJ; Goldman S; Robison NJ; Allen JC; Viskochil DH; Gutmann DH; Perentesis JP; Korf BR; Fisher MJ; Kieran MW;
Pediatr Blood Cancer; 2021 Apr; 68(4):e28833. PubMed ID: 33336845
[TBL] [Abstract][Full Text] [Related]
31. Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1.
Kelly JP; Weiss AH
Neuro Oncol; 2013 Nov; 15(11):1560-7. PubMed ID: 24101736
[TBL] [Abstract][Full Text] [Related]
32. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
33. Optic pathway glioma in children: 10 years of experience in a single institution.
Doganis D; Pourtsidis A; Tsakiris K; Baka M; Kouri A; Bouhoutsou D; Varvoutsi M; Servitzoglou M; Dana H; Kosmidis H
Pediatr Hematol Oncol; 2016 Mar; 33(2):102-8. PubMed ID: 27007263
[TBL] [Abstract][Full Text] [Related]
34. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.
Avery RA; Bouffet E; Packer RJ; Reginald A
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1034-8. PubMed ID: 23329671
[TBL] [Abstract][Full Text] [Related]
35. Visual outcome following chemotherapy for progressive optic pathway gliomas.
Shofty B; Ben-Sira L; Freedman S; Yalon M; Dvir R; Weintraub M; Toledano H; Constantini S; Kesler A
Pediatr Blood Cancer; 2011 Sep; 57(3):481-5. PubMed ID: 21241008
[TBL] [Abstract][Full Text] [Related]
36. Handheld optical coherence tomography during sedation in young children with optic pathway gliomas.
Avery RA; Hwang EI; Ishikawa H; Acosta MT; Hutcheson KA; Santos D; Zand DJ; Kilburn LB; Rosenbaum KN; Rood BR; Schuman JS; Packer RJ
JAMA Ophthalmol; 2014 Mar; 132(3):265-71. PubMed ID: 24435762
[TBL] [Abstract][Full Text] [Related]
37. Treatment burden and long-term health deficits of patients with low-grade gliomas or glioneuronal tumors diagnosed during the first year of life.
Liu APY; Hastings C; Wu S; Bass JK; Heitzer AM; Ashford J; Vestal R; Hoehn ME; Ghazwani Y; Acharya S; Conklin HM; Boop F; Merchant TE; Gajjar A; Qaddoumi I
Cancer; 2019 Apr; 125(7):1163-1175. PubMed ID: 30620400
[TBL] [Abstract][Full Text] [Related]
38. Natural history and outcome of optic pathway gliomas in children.
Nicolin G; Parkin P; Mabbott D; Hargrave D; Bartels U; Tabori U; Rutka J; Buncic JR; Bouffet E
Pediatr Blood Cancer; 2009 Dec; 53(7):1231-7. PubMed ID: 19621457
[TBL] [Abstract][Full Text] [Related]
39. Ganglion cell layer-inner plexiform layer thickness and vision loss in young children with optic pathway gliomas.
Gu S; Glaug N; Cnaan A; Packer RJ; Avery RA
Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1402-8. PubMed ID: 24519429
[TBL] [Abstract][Full Text] [Related]
40. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part I: Treatment modalities of radiation therapy.
Kortmann RD; Timmermann B; Taylor RE; Scarzello G; Plasswilm L; Paulsen F; Jeremic B; Gnekow AK; Dieckmann K; Kay S; Bamberg M
Strahlenther Onkol; 2003 Aug; 179(8):509-20. PubMed ID: 14509949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
